Henlius Biotech’s Biosimilar Rituximab Receives First Overseas Marketing Approval from Peru
Shanghai Henlius Biotech Co., Ltd (HKG: 2696), a biopharmaceutical company based in China, has announced...
Biosimilars
Luye Pharma’s Subsidiary Gets NMPA Green Light for Biosimilar Xgeva
Shandong Boan Biotechnology Co., Ltd (HKG: 6955), a controlling subsidiary of China-based Luye Pharma Group...
Henlius Biotech’s Denosumab Biosimilar Secures EMA Review for European Market Entry
Shanghai Henlius Biotech Inc. (HKG: 2696), a biopharmaceutical company based in China, has announced that...
Sandoz Receives European Commission Approval for Biosimilars Wyost and Jubbonti
The European Commission (EC) has granted registration approval to Sandoz, a Switzerland-headquartered pharmaceutical company (SWX:...
Alvotech and Dr. Reddy’s Partner to Challenge Amgen’s Denosumab with Biosimilar AVT03
Amgen’s (NASDAQ: AMGN) dominance in the bone treatment market with its blockbuster drugs Xgeva and...
Fosun Pharmaceutical’s Humira Biosimilar Gains New Indications with NMPA Approval
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its biosimilar...
Tonghua Dongbao Pharmaceuticals Begins Clinical Trial for Xultophy Biosimilar
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced the dosing of the...
Bio-Thera Solutions’ BAT1806 Receives Positive CHMP Recommendation for EU Approval
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that the Committee for Medicinal Products for...
US FDA Greenlights Henlius Biotech’s Hanquyou as Biosimilar to Roche’s Herceptin
Shanghai Henlius Biotech Inc. (HKG: 2696) has achieved a significant milestone with the US Food...
Sandoz’s Partner Samsung Bioepis Scores EC Approval for Stelara Biosimilar Pyzchiva
Switzerland-headquartered Sandoz (SWX: SDZ) has announced that the European Commission (EC) has granted approval for...
Luye Pharma’s Subsidiary Boan Biotech Completes Phase III Trial for Eylea Biosimilar BA9101
Shandong Boan Biotechnology Co., Ltd., a subsidiary of China-based Luye Pharma Group (HKG: 2186), has...
Shanghai Henlius Reports Phase III Success for HLX14 in Osteoporosis Treatment
Shanghai Henlius Biotech Inc. (HKG: 2696), based in China, has announced that its global, multi-center...
Mabwell Bioscience Receives NMPA Approval for Biosimilar Version of Amgen’s Xgeva
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received market approval...
Jiuyuan Gene’s Semaglutide Biosimilar Market Filing Accepted for Review in China
Hangzhou Jiuyuan Gene Engineering Co., Ltd., based in China, has announced that its market approval...
Shanghai Institute’s Biosimilar Rituximab Approved by NMPA for Lymphoma Treatments
Shanghai Institute of Biological Products Co., Ltd has announced that its biosimilar version of Roche/Genentech’s...
Dr. Reddy’s Launches Biosimilar Versavo in UK to Challenge Roche’s Cancer Therapy Avastin
Dr. Reddy’s Laboratories (NYSE: RDY), a prominent Indian pharmaceutical company, has launched its biosimilar Versavo...
Bio-Thera Solutions and SteinCares Ink Licensing Deal for LatAm Biosimilar Distribution
Bio-Thera Solutions (SHA: 688177), a Chinese biopharmaceutical company, has entered into a licensing agreement with...
Henlius Biotech’s HER2 Targeting Biosimilar Secures Thai and Philippine Approvals
Shanghai Henlius Biotech Inc., (HKG: 2696) a leading China-based biotech firm, has announced that its...
Sandoz Achieves FDA Milestone with Approval of First US Denosumab Biosimilars
The US Food and Drug Administration (FDA) has granted Sandoz (SWX: SDZ), a Switzerland-based pharmaceutical...
Fosun Pharmaceutical’s HanDaYuan Seeks NMPA Approval for Expanded Indications in Autoimmune Treatments
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...